{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:10:16Z","timestamp":1725257416920},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02461-y","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T05:02:19Z","timestamp":1722920539000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study"],"prefix":"10.1007","volume":"41","author":[{"given":"Asim","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abantika","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarika","family":"Tilwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkataramanan","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"3","key":"2461_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10061","key":"2461_CR2","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. Bladder cancer. Lancet. 2016;388(10061):2796\u2013810.","journal-title":"Lancet"},{"issue":"5","key":"2461_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)\u20142019 update. Eur Urol. 2019;76(5):639\u201357.","journal-title":"Eur Urol"},{"issue":"2","key":"2461_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5430\/jst.v4n2p25","volume":"4","author":"BA Teply","year":"2014","unstructured":"Teply BA, Kim JJ. Systemic therapy for bladder cancer\u2014a medical oncologist\u2019s perspective. J Solid Tumors. 2014;4(2):25\u201335.","journal-title":"J Solid Tumors"},{"issue":"3","key":"2461_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/SPC.0000000000000505","volume":"14","author":"A Desilets","year":"2020","unstructured":"Desilets A, Adam JP, Soulieres D. Management of cisplatin-associated toxicities in bladder cancer patients. Curr Opin Support Palliat Care. 2020;14(3):286\u201392.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"12","key":"2461_CR6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.ejca.2012.04.002","volume":"48","author":"R Morales-Barrera","year":"2012","unstructured":"Morales-Barrera R, Bellmunt J, Suarez C, Valverde C, Guix M, Serrano C, et al. Cisplatin and gemcitabine administered every 2\u00a0week in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012;48(12):1816\u201321.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2461_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1586\/era.11.201","volume":"12","author":"RM Drayton","year":"2012","unstructured":"Drayton RM, Catto JW. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther. 2012;12(2):271\u201381.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"34","key":"2461_CR8","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.18632\/oncotarget.27696","volume":"11","author":"G Sathe","year":"2020","unstructured":"Sathe G, George IA, Deb B, Jain AP, Patel K, Nayak B, et al. Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1. Oncotarget. 2020;11(34):3244\u201355.","journal-title":"Oncotarget"},{"issue":"15","key":"2461_CR9","doi-asserted-by":"publisher","first-page":"13539","DOI":"10.18632\/oncotarget.3841","volume":"6","author":"P Kumar","year":"2015","unstructured":"Kumar P, Nandi S, Tan TZ, Ler SG, Chia KS, Lim WY, et al. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget. 2015;6(15):13539\u201349.","journal-title":"Oncotarget"},{"key":"2461_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fonc.2019.00435","volume":"9","author":"J Sharma","year":"2019","unstructured":"Sharma J, Deb B, George IA, Kapil S, Coral K, Kakkar N, et al. Somatic mutations profile of a young patient with metastatic urothelial carcinoma reveals mutations in genes involved in ion channels. Front Oncol. 2019;9:435.","journal-title":"Front Oncol"},{"issue":"1","key":"2461_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-022-01517-9","volume":"21","author":"ZD Shi","year":"2022","unstructured":"Shi ZD, Hao L, Han XX, Wu ZX, Pang K, Dong Y, et al. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Mol Cancer. 2022;21(1):37.","journal-title":"Mol Cancer"},{"issue":"1","key":"2461_CR12","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1038\/s41467-017-02320-7","volume":"8","author":"D Liu","year":"2017","unstructured":"Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017;8(1):2193.","journal-title":"Nat Commun"},{"key":"2461_CR13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/TCRM.S158753","volume":"14","author":"D Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018;14:1019\u201340.","journal-title":"Ther Clin Risk Manag"},{"issue":"27","key":"2461_CR14","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454\u201361.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2461_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41585-019-0208-0","volume":"16","author":"C Alifrangis","year":"2019","unstructured":"Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol. 2019;16(8):465\u201383.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"2461_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q","volume":"89","author":"MP Zeegers","year":"2000","unstructured":"Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89(3):630\u20139.","journal-title":"Cancer"},{"issue":"4","key":"2461_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10552-007-9104-7","volume":"19","author":"AS Felix","year":"2008","unstructured":"Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M, et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control. 2008;19(4):421\u20139.","journal-title":"Cancer Causes Control"},{"issue":"6","key":"2461_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.1464-410X.2003.04421.x","volume":"92","author":"P Crow","year":"2003","unstructured":"Crow P, Ritchie AW. National and international variation in the registration of bladder cancer. BJU Int. 2003;92(6):563\u20136.","journal-title":"BJU Int"},{"key":"2461_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/03008880802285032","volume":"218","author":"DM Parkin","year":"2008","unstructured":"Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008;218:12\u201320.","journal-title":"Scand J Urol Nephrol Suppl"},{"issue":"3","key":"2461_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","volume":"27","author":"M Ploeg","year":"2009","unstructured":"Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289\u201393.","journal-title":"World J Urol"},{"issue":"3","key":"2461_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","volume":"69","author":"J Leal","year":"2016","unstructured":"Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European union. Eur Urol. 2016;69(3):438\u201347.","journal-title":"Eur Urol"},{"issue":"8","key":"2461_CR22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904.","journal-title":"World J Urol"},{"issue":"4","key":"2461_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0976-500X.119704","volume":"4","author":"A Abidi","year":"2013","unstructured":"Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 2013;4(4):230\u20137.","journal-title":"J Pharmacol Pharmacother"},{"issue":"3","key":"2461_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.tranon.2015.04.002","volume":"8","author":"S Vallo","year":"2015","unstructured":"Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, et al. Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics. Transl Oncol. 2015;8(3):210\u20136.","journal-title":"Transl Oncol"},{"issue":"9","key":"2461_CR25","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00432-016-2204-6","volume":"142","author":"M Gerwing","year":"2016","unstructured":"Gerwing M, Jacobsen C, Dyshlovoy S, Hauschild J, Rohlfing T, Oing C, et al. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. J Cancer Res Clin Oncol. 2016;142(9):1979\u201394.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2461_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.clgc.2021.02.001","volume":"19","author":"A Challapalli","year":"2021","unstructured":"Challapalli A, Masson S, White P, Dailami N, Pearson S, Rowe E, et al. A single-arm phase II trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder. Clin Genitourin Cancer. 2021;19(4):325\u201332.","journal-title":"Clin Genitourin Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02461-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T05:11:06Z","timestamp":1725253866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02461-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["2461"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02461-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the experiments were performed using commercially available cell lines and hence no ethical approval was needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"219"}}